January 1, 1970 (Vol. , No. )
Sascha Hasan, Ph.D. Sanguine Biosciences
More pharmaceutical and biotech companies are realizing the importance of patient engagement from the preclinical R&D process all the way through the commercialization phase.
For years, patients and their caregivers were mostly uninformed outsiders as pharmaceutical companies and research institutes developed new drugs and strategies for future growth.
Now, however, in order to increase brand awareness or accelerate predictive medicine development, more and more pharmaceutical and biotechnology companies realize the importance of patient engagement, starting at the preclinical R&D process all the way through clinical trials and the commercialization phase.
Despite all the ongoing efforts to engage patients, “Big Pharma ranks near bottom in patient attitudes”. The FiercePharma article from January 18, 2013, briefly describes the outcome of a survey of 500 international, national, and regional patient groups, and their views of the different stages of the drug/device development. The survey indicates that patients found drug companies “too secretive, doing a poor job of letting patients know about adverse drug event news.” Consequently, many patients have issues with the industry’s integrity.
Nevertheless, companies are slowly getting better in bridging the gap between industry and patients. Gaining patients’ trust will be a long-term task, an infinite circle of strategizing, implementing, observing, and analyzing. Depending on a) purpose, b) stage of drug or biomarker development, and c) patient or, eventually, caregiver demographics, one has to develop appropriate recruitment/engagement strategies.
A) Preclinical Drug Development
The Status Quo:
For drug target/validation studies or biomarker development researchers oftentimes need larger quantities of patient samples (often, from hundreds of patients) in order to obtain statistically significant data. Hospital-based biobanks and, eventually, independent biobanks, are organizations that usually have direct access to patients. However, often it becomes quite time-consuming to source needed samples.
As Matt Jones, staff reporter for GenomeWeb Daily News, pointed out in his most recent article:
- Two-thirds of the nation’s biobanks were established over the past decade—it is estimated that there are about 800 biobanks within the U.S.
- The increase of genomics and related large-scale studies have led biobanks to play an increasingly central part in biomedical R&D—genomic research appears as if it is a key driver in the “biobank explosion”.
In short, based on increasing demand, competition is increasing, and given the fact that sequencing costs are rapidly decreasing, one can imagine that this trend will continue. But as biobanks increase and specific patient populations stay the same (especially rare diseases), sample/data sourcing becomes a big issue.
Matt Jones points out that with all the data being generated, certain new regulations might “kick in” within the next few years. Privacy protection always was, and increasingly will be, a topic of many future discussions—especially after the Yaniv Ehrlich’s recent Science article: “Identifying Personal Genomes by Surname Inference”. No matter what your attitude towards these findings is, patients that become aware of these potential “threats” to privacy will increasingly fear breach of “protected” private data and therefore probably be less willing to donate and share their valuable biosamples and medical information. (If interested, further comments can be read in a New York Times article from January 17, 2013: “Web Hunt for DNA Sequences Leaves Privacy Compromised”).
Why Engage with Patients?
It is necessary to connect and build trust. Social media is a powerful tool to engage in two-way-communication with patients: for instance, at the biobank Sanguine Biosciences’ patient blog, patients are writing about their experiences, their fears, and how they overcame those. The company realizes that it is important to actually work with patients to learn about and educate them: learning, listening, and educating needs to go both ways.
Furthermore, increased transparency is another way to develop trust. For instance, in the near future, the biobank will notify patients about the impact their samples made by informing them about where they have been sent to and/or for what purpose they were used for. Sure, some companies or research institutes will not allow communicating any information at all; however, others are very interested in working with companies to help them bridge the company-patient-gap.
Additional engagement strategies include partnerships with nonprofit organizations to provide patients the right education and to learn first-hand about the difficulties patients are dealing with on a daily basis.
Ultimately, if there is already an existing hospital/biobank-patients bond, sourcing samples and data will be faster and less costly, and longitudinal collection studies will become easier. Recruiting donors for clinical trials (i.e., based on their genetic profile) will become easier, too.
B) Clinical Trials Phase
Oftentimes, pharmas, CROs, and clinics/hospitals are faced with relatively high patient recruitment costs (about $2000/patient) and/or lengthy recruitment periods. Having engaged patients already “on-hand” might therefore lead to reduced recruitment cost and time.
The Pfizer Way:
As a former Pfizer R&D executive, John LaMattina, suggested, big pharma should consider providing more transparency regarding payments to physicians and data derived from clinical trials. However, as Todd Kolm, director, Emerging Channel Strategy at Pfizer pointed out: “Because of the regulatory environment, we’re not able to engage in a true dialogue.”
Furthermore, what makes patient engagement even more difficult is the relatively poor understanding of new media channels, a lack of FDA guidance, a lack of pharmaceutical executives promoting it, the scarcity of demonstrated success stories, the often inadequate resources allocated to new patient engagement strategies, and the simple fact that it is often not really perceived as a must-have, value-added strategy.
Nonetheless, Pfizer’s REMOTE (Research on Electronic Monitoring of OAB [overactive bladder] Treatment Experience) trial proved that through innovative thinking, courage, and implementation of completely new strategies, hurdles can slowly be overcome.
REMOTE, which ended in mid-2012, was the first randomized virtual clinical trial conducted under an IND application.
The main problem, however, was recruiting the right patients needed for the study. This was mainly caused by being very regulatory cautious so no wrong patients would enter the virtual trial.
To quote Craig Lipset, Worldwide Head of Clinical Innovation at Pfizer: “As an industry, we will continue to fail to recruit patients in our studies if we cannot create an ecosystem of patients already engaged and aware about research studies and research participation.”
The good news: Having a web-based recruiting site simplified patient recruitment (including consenting) and allowed patients to participate from their own home; web-based and mobile platforms were used to capture self-reported data from those patients. In addition, primary care physicians engaged with patients by screening and caring for them during the trial. Furthermore, patients received their data at the end of the trial period and were able to even share those with their physician.
C) Post-Approval/Commercialization Phase
Pharmaceutical biotechnology companies are slowly becoming more patient-centric. Belgium-based UCB, for example, developed a very patient-focused website, engaging patients through education and disease-specific patient-support programs.
Other companies are also trying to bridge the gap to their patients. Major firms such as Biogen Idec, Pfizer, and French pharmaceutical giant Sanofi, the parent of Genzyme, are partnering on a number of initiatives with patient groups such as the Michael J. Fox Foundation for Parkinson’s Research.
Taken together, it is key to provide top-quality, objective, reliable, unbiased education, training, and information to patient organizations and patients at large on all aspects of R&D, in order for patients to get involved and become empowered players in the medical drug development process.
Sascha Hasan, Ph.D., is CSO at Sanguine Biosciences. He received his Ph.D. in Pharmacology at UCLA David Geffen School of Medicine, and his MBA at the University of Southern California. He can be reached at [email protected].
Big Pharma ranks near bottom in patient attitudes – FiercePharma http://www.fiercepharma.com/story/big-pharma-ranks-near-bottom-patient-attitudes/2013-01-18#ixzz2JEbcBxOV
U.S. Sees Boom in Diverse Range of Biobanks, But Regulations are Lacking – GenomeWeb http://www.genomeweb.com/us-sees-boom-diverse-range-biobanks-regulations-are-lacking
Identifying Personal Genomes by Surname Inference – Science http://www.sciencemag.org/content/339/6117/321.abstract
Web Hunt for DNA Sequences Leaves Privacy Compromised – New York Times http://www.nytimes.com/2013/01/18/health/search-of-dna-sequences-reveals-full-identities.html?pagewanted=1&_r=0
Between patients and pharmas online, a disconnect – Medical Marketing & Media http://www.mmm-online.com/between-patients-and-pharmas-online-a-disconnect/article/260723/
Pfizer Perseveres In Pioneering Virtual Clinical Trials – Life Science Leader http://lifescienceleader.com/blogs/contributing-editors-2/item/4363-pfizer-perseveres-in-pioneering-virtual-clinical-trials